$2.3
Live
0.43%
Downside
Day's Volatility :4.58%
Upside
4.17%
17.39%
Downside
52 Weeks Volatility :57.59%
Upside
48.66%
Period | Armata Pharmaceuticals Inc | Index (Russel 2000) |
---|---|---|
3 Months | -20.37% | 0.0% |
6 Months | -5.78% | 0.0% |
1 Year | 12.08% | 0.0% |
3 Years | -23.71% | -23.0% |
Market Capitalization | 85.4M |
Book Value | -$1.27 |
Earnings Per Share (EPS) | -1.86 |
Wall Street Target Price | 7.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1130.87% |
Return On Assets TTM | -25.09% |
Return On Equity TTM | -3439.35% |
Revenue TTM | 3.7M |
Revenue Per Share TTM | 0.1 |
Quarterly Revenue Growth YOY | 21.4% |
Gross Profit TTM | -29.5M |
EBITDA | -40.9M |
Diluted Eps TTM | -1.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.02 |
EPS Estimate Next Year | -1.57 |
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Next Quarter | -0.42 |
What analysts predicted
Upside of 204.35%
Sell
Neutral
Buy
Armata Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Armata Pharmaceuticals Inc | 0.21% | -5.78% | 12.08% | -23.71% | -42.32% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Armata Pharmaceuticals Inc | NA | NA | NA | -1.02 | -34.39 | -0.25 | NA | -1.27 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Armata Pharmaceuticals Inc | Buy | $85.4M | -42.32% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Armata Pharmaceuticals Inc
Revenue is down for the last 2 quarters, 1.52M → 966.0K (in $), with an average decrease of 36.8% per quarter
Netprofit is up for the last 2 quarters, -25.02M → 8.98M (in $), with an average increase of 378.4% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 63.5%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 68.5%
c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
Organization | Armata Pharmaceuticals Inc |
Employees | 66 |
CEO | Dr. Deborah L. Birx M.D. |
Industry | Biotechnology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.30
-2.75%
Invesco Bulletshares 2025 Hi
$2.30
-2.75%
Schwab International Dividend Equity Etf
$2.30
-2.75%
Blockchain Coinvestors Acquisition Corp.
$2.30
-2.75%
Allgiant Travel Company
$2.30
-2.75%
Rogers Corp
$2.30
-2.75%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.30
-2.75%
Iheartmedia
$2.30
-2.75%
Lightpath Technologies Inc
$2.30
-2.75%